For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.
Scope of the Report:
This report focuses on the Anti-Obesity Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for the drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population were obese in 2014. In developing countries the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries.
The worldwide market for Anti-Obesity Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Bristol-Myers Squibb
- Eisai Company
- FlaxoSithKline plc.
- Novo Nordisk
- Alizyme
- BoehringerIngelheim GmbH
- Pfizer
- Takeda Pharmaceutical
- Rhythm Pharmaceuticals
- Shionogi USA
- Vivus
- Zafgen
- Norgine Pharmaceuticals Ltd.
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Centrally Acting Anti-obesity Drugs
- Peripherally Acting Anti-obesity Drugs
Market Segment by Applications, can be divided into
- Hospital Use
- Clinic Use
- Household
- Other
There are 15 Chapters to deeply display the global Anti-Obesity Therapeutics market.
Chapter 1, to describe Anti-Obesity Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-Obesity Therapeutics, with sales, revenue, and price of Anti-Obesity Therapeutics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Obesity Therapeutics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-Obesity Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-Obesity Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source